In silico approaches and tools for the prediction of drug metabolism and fate: A review

The fate of administered drugs is largely influenced by their metabolism. For example, endogenous enzyme-catalyzed conversion of drugs may result in therapeutic inactivation or activation or may transform the drugs into toxic chemical compounds. This highlights the importance of drug metabolism in drug discovery and development, and accounts for the wide variety of experimental technologies that provide insights into the fate of drugs. In view of the high cost of traditional drug development, a number of computational approaches have been developed for predicting the metabolic fate of drug candidates, allowing for screening of large numbers of chemical compounds and then identifying a small number of promising candidates. In this review, we introduce in silico approaches and tools that have been developed to predict drug metabolism and fate, and assess their potential to facilitate the virtual discovery of promising drug candidates. We also provide a brief description of various recent models for predicting different aspects of enzyme-drug reactions and provide a list of recent in silico tools used for drug metabolism prediction.

[1]  Carolina Horta Andrade,et al.  Advances in methods for predicting phase I metabolism of polyphenols. , 2014, Current drug metabolism.

[2]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[3]  H Kubinyi,et al.  Chance favors the prepared mind--from serendipity to rational drug design. , 1999, Journal of receptor and signal transduction research.

[4]  Thierry Langer,et al.  Predicting drug metabolism induction in silico. , 2006, Current topics in medicinal chemistry.

[5]  David S. Wishart,et al.  HMDB: a knowledgebase for the human metabolome , 2008, Nucleic Acids Res..

[6]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[7]  J. Gready,et al.  Combining docking and molecular dynamic simulations in drug design , 2006, Medicinal research reviews.

[8]  Byunghan Lee,et al.  Deep learning in bioinformatics , 2016, Briefings Bioinform..

[9]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.

[10]  C. Andrade,et al.  In silico prediction of drug metabolism by P450. , 2014, Current drug metabolism.

[11]  J. Blake,et al.  On the Connection between Chemical Constitution and Physiological Action , 1886, Nature.

[12]  Aurélien Grosdidier,et al.  Fast docking using the CHARMM force field with EADock DSS , 2011, J. Comput. Chem..

[13]  Thomas Fox,et al.  Machine learning techniques for in silico modeling of drug metabolism. , 2006, Current topics in medicinal chemistry.

[14]  T. Akabane,et al.  A practical and direct comparison of intrinsic metabolic clearance of several non-CYP enzyme substrates in freshly isolated and cryopreserved hepatocytes. , 2012, Drug metabolism and pharmacokinetics.

[15]  Mitchell A. Lazar,et al.  De-Meaning of Metabolism , 2012, Science.

[16]  Vladimir B Bajic,et al.  In silico toxicology: computational methods for the prediction of chemical toxicity , 2016, Wiley interdisciplinary reviews. Computational molecular science.

[17]  Jiunn H. Lin,et al.  Role of P-Glycoprotein in Pharmacokinetics , 2003, Clinical pharmacokinetics.

[18]  U. Tillmann,et al.  A systematic approach for evaluating the quality of experimental toxicological and ecotoxicological data. , 1997, Regulatory toxicology and pharmacology : RTP.

[19]  Alex M. Clark,et al.  Accessible Machine Learning Approaches for Toxicology , 2018 .

[20]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[21]  Shufeng Zhou Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. , 2008, Current drug metabolism.

[22]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[23]  Lu Zhang,et al.  From machine learning to deep learning: progress in machine intelligence for rational drug discovery. , 2017, Drug discovery today.

[24]  E. Ovidi,et al.  Natural products for human health: an historical overview of the drug discovery approaches , 2018, Natural product research.

[25]  B. Ring,et al.  In vitro methods for assessing human hepatic drug metabolism: their use in drug development. , 1993, Drug metabolism reviews.

[26]  Helmut Segner,et al.  Data quality assessment for in silico methods: A survey of approaches and needs , 2010 .

[27]  Ying Xue,et al.  Quantitative structure–activity relationship study of influenza virus neuraminidase A/PR/8/34 (H1N1) inhibitors by genetic algorithm feature selection and support vector regression , 2013 .

[28]  C. Hansch,et al.  p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure , 1964 .

[29]  N. Meanwell,et al.  The expanding role of prodrugs in contemporary drug design and development , 2018, Nature Reviews Drug Discovery.

[30]  Antonio Lavecchia,et al.  Machine-learning approaches in drug discovery: methods and applications. , 2015, Drug discovery today.

[31]  Samina Kausar,et al.  An automated framework for QSAR model building , 2018, Journal of Cheminformatics.

[32]  S. Hochreiter,et al.  DeepTox: Toxicity prediction using deep learning , 2017 .

[33]  Yong Wang,et al.  Site of metabolism prediction for six biotransformations mediated by cytochromes P450 , 2009, Bioinform..

[34]  Eric T. Kim,et al.  How does a drug molecule find its target binding site? , 2011, Journal of the American Chemical Society.

[35]  Hongbin Yang,et al.  Multiclassification Prediction of Enzymatic Reactions for Oxidoreductases and Hydrolases Using Reaction Fingerprints and Machine Learning Methods , 2018, J. Chem. Inf. Model..

[36]  Emilio Benfenati,et al.  In silico methods to predict drug toxicity. , 2013, Current opinion in pharmacology.

[37]  Lu Tan,et al.  Software for Metabolism Prediction , 2014 .

[38]  Lydia E. Kavraki,et al.  Molecular docking: a problem with thousands of degrees of freedom , 2001, Proceedings 2001 ICRA. IEEE International Conference on Robotics and Automation (Cat. No.01CH37164).

[39]  Chris Oostenbrink,et al.  Computational prediction of drug binding and rationalisation of selectivity towards cytochromes P450 , 2008 .

[40]  D. Koshland The Key–Lock Theory and the Induced Fit Theory , 1995 .

[41]  Olexandr Isayev,et al.  Transforming Computational Drug Discovery with Machine Learning and AI. , 2018, ACS medicinal chemistry letters.

[42]  Vinícius Gonçalves Maltarollo,et al.  Applying machine learning techniques for ADME-Tox prediction: a review , 2015, Expert opinion on drug metabolism & toxicology.

[43]  Simone Brogi,et al.  Identification of novel fluorescent probes preventing PrPSc replication in prion diseases. , 2017, European journal of medicinal chemistry.

[44]  Guo-Wei Wei,et al.  Quantitative Toxicity Prediction Using Topology Based Multitask Deep Neural Networks , 2017, J. Chem. Inf. Model..

[45]  Russ B Altman,et al.  Machine learning in chemoinformatics and drug discovery. , 2018, Drug discovery today.

[46]  R. Kream,et al.  Endogenous morphine: up-to-date review 2011. , 2012, Folia biologica.

[47]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[48]  R L Nation,et al.  Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine. , 2003, British journal of clinical pharmacology.

[49]  Yoshihiro Yamanishi,et al.  Prediction of drug–target interaction networks from the integration of chemical and genomic spaces , 2008, ISMB.

[50]  Saeed Alqahtani,et al.  In silico ADME-Tox modeling: progress and prospects , 2017, Expert opinion on drug metabolism & toxicology.

[51]  G. Mangiatordi,et al.  Applicability Domain for QSAR models: where theory meets reality , 2016 .

[52]  J C Gertrudes,et al.  Machine learning techniques and drug design. , 2012, Current medicinal chemistry.

[53]  D. Yin,et al.  Using molecular docking-based binding energy to predict toxicity of binary mixture with different binding sites. , 2013, Chemosphere.

[54]  Juan M. Luco,et al.  QSAR Based on Multiple Linear Regression and PLS Methods for the Anti-HIV Activity of a Large Group of HEPT Derivatives , 1997, J. Chem. Inf. Comput. Sci..

[55]  Vladimir Poroikov,et al.  SOMP: web server for in silico prediction of sites of metabolism for drug-like compounds , 2015, Bioinform..

[56]  M. Schwab,et al.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, Pharmacology & therapeutics.

[57]  Taeho Jo,et al.  Improving Protein Fold Recognition by Deep Learning Networks , 2015, Scientific Reports.

[58]  Raghuraman Venkatapathy,et al.  Developmental toxicity prediction. , 2013, Methods in molecular biology.

[59]  Rona R. Ramsay,et al.  A perspective on multi-target drug discovery and design for complex diseases , 2018, Clinical and Translational Medicine.

[60]  Yi Wang,et al.  In silico search of putative adverse drug reaction related proteins as a potential tool for facilitating drug adverse effect prediction. , 2006, Toxicology letters.

[61]  Yojiro Sakiyama,et al.  Predicting human liver microsomal stability with machine learning techniques. , 2008, Journal of molecular graphics & modelling.

[62]  Nic Fleming,et al.  How artificial intelligence is changing drug discovery , 2018, Nature.

[63]  Zhiwei Cao,et al.  Insight into potential toxicity mechanisms of melamine: an in silico study. , 2011, Toxicology.

[64]  Z R Li,et al.  Machine learning approaches for predicting compounds that interact with therapeutic and ADMET related proteins. , 2007, Journal of pharmaceutical sciences.

[65]  Andrew A Somogyi,et al.  Advances in drug metabolism and pharmacogenetics research in Australia , 2017, Pharmacological research.

[66]  Christopher R. Corbeil,et al.  Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go , 2008, British journal of pharmacology.

[67]  Jian Peng,et al.  Protein Secondary Structure Prediction Using Deep Convolutional Neural Fields , 2015, Scientific Reports.

[68]  A. Nafziger,et al.  Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. , 2002, The American journal of medicine.

[69]  Nidhi Singh,et al.  Integrated machine learning, molecular docking and 3D-QSAR based approach for identification of potential inhibitors of trypanosomal N-myristoyltransferase. , 2016, Molecular bioSystems.

[70]  Jianlin Cheng,et al.  A Deep Learning Network Approach to ab initio Protein Secondary Structure Prediction , 2015, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[71]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[72]  H. Carlson Protein flexibility and drug design: how to hit a moving target. , 2002, Current opinion in chemical biology.

[73]  Michael I. Jordan,et al.  Machine learning: Trends, perspectives, and prospects , 2015, Science.

[74]  Li Li,et al.  In silico prediction of cytochrome P450-mediated drug metabolism. , 2011, Combinatorial chemistry & high throughput screening.

[75]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[76]  Mingshe Zhu,et al.  In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201) , 2016, Forensic Toxicology.

[77]  Petra Schneider,et al.  Generative Recurrent Networks for De Novo Drug Design , 2017, Molecular informatics.

[78]  William J. Allen,et al.  DOCK 6: Impact of new features and current docking performance , 2015, J. Comput. Chem..

[79]  Alka Kurup C-QSAR: a database of 18,000 QSARs and associated biological and physical data , 2003, J. Comput. Aided Mol. Des..

[80]  Y. Z. Chen,et al.  Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. , 2001, Journal of molecular graphics & modelling.

[81]  Jonathan D. Hirst,et al.  New approaches to QSAR: Neural networks and machine learning , 1993 .

[82]  Hao Zhu,et al.  Experimental Errors in QSAR Modeling Sets: What We Can Do and What We Cannot Do , 2017, ACS omega.

[83]  Antje Chang,et al.  BRENDA , the enzyme database : updates and major new developments , 2003 .

[84]  Hui Zhang,et al.  Applications of Machine Learning Methods in Drug Toxicity Prediction. , 2018, Current topics in medicinal chemistry.

[85]  Michelle L Coote,et al.  Molecular dynamics-driven drug discovery: leaping forward with confidence. , 2017, Drug discovery today.

[86]  John B. O. Mitchell Machine learning methods in chemoinformatics , 2014, Wiley interdisciplinary reviews. Computational molecular science.

[87]  O. Drummer,et al.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects , 2011, Forensic science, medicine, and pathology.

[88]  Aaron Park,et al.  In silico prediction of potential chemical reactions mediated by human enzymes , 2018, BMC Bioinformatics.

[89]  R. W. Hansen,et al.  Journal of Health Economics , 2016 .

[90]  Bing Niu,et al.  Prediction of Substrate-Enzyme-Product Interaction Based on Molecular Descriptors and Physicochemical Properties , 2013, BioMed research international.

[91]  S. Free,et al.  A MATHEMATICAL CONTRIBUTION TO STRUCTURE-ACTIVITY STUDIES. , 1964, Journal of medicinal chemistry.

[92]  Supa Hannongbua,et al.  In-silico ADME models: a general assessment of their utility in drug discovery applications. , 2011, Current topics in medicinal chemistry.

[93]  C. Ong,et al.  In vitro and in silico Approaches to Study Cytochrome P450-Mediated Interactions. , 2017, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[94]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[95]  Tom L Blundell,et al.  Advantages of fine-grained side chain conformer libraries. , 2003, Protein engineering.

[96]  S. Hannongbua,et al.  Quantitative Structure–Activity Relationship (QSAR) Methods for the Prediction of Substrates, Inhibitors, and Inducers of Metabolic Enzymes , 2014 .

[97]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[98]  D. Flockhart,et al.  In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. , 2000, British journal of clinical pharmacology.

[99]  W. L. Jorgensen The Many Roles of Computation in Drug Discovery , 2004, Science.

[100]  Z R Li,et al.  Quantitative structure-pharmacokinetic relationships for drug clearance by using statistical learning methods. , 2006, Journal of molecular graphics & modelling.

[101]  David F. V. Lewis,et al.  Structure–activity relationship for human cytochrome P450 substrates and inhibitors , 2002, Drug metabolism reviews.

[102]  Yun Pyo Kang,et al.  Recent advances in cancer metabolism: a technological perspective , 2018, Experimental & Molecular Medicine.

[103]  Scott Boyer,et al.  Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models , 2007, J. Comput. Aided Mol. Des..

[104]  T. Lynch,et al.  The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. , 2007, American family physician.

[105]  C. George Priya Doss,et al.  Computational approaches and resources in single amino acid substitutions analysis toward clinical research. , 2014, Advances in protein chemistry and structural biology.

[106]  Uko Maran,et al.  QSAR DataBank repository: open and linked qualitative and quantitative structure–activity relationship models , 2015, Journal of Cheminformatics.

[107]  Sean Ekins The Next Era: Deep Learning in Pharmaceutical Research , 2016, Pharmaceutical Research.

[108]  Yan Xu,et al.  Deep learning of feature representation with multiple instance learning for medical image analysis , 2014, 2014 IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP).

[109]  Ovidiu Ivanciuc Machine Learning Quantitative Structure-Activity Relationships (QSAR) for Peptides Binding to the Human Amphiphysin-1 SH3 Domain , 2009 .

[110]  K. Chou,et al.  Recent advances in QSAR and their applications in predicting the activities of chemical molecules, peptides and proteins for drug design. , 2008, Current protein & peptide science.

[111]  Dan Li,et al.  ADMET Evaluation in Drug Discovery. 16. Predicting hERG Blockers by Combining Multiple Pharmacophores and Machine Learning Approaches. , 2016, Molecular pharmaceutics.

[112]  David Jou,et al.  Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface. , 2014, Journal of medicinal chemistry.